Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Appeals Court Says Rituxan, Avastin Do Not Infringe Sanofi Patents

RELATED NEWS
Trade SNY now with 

An appeals court on Thursday upheld a lower court's ruling that the cancer drugs Rituxan and Avastin of Swiss drug maker Roche Holding AG's (RHHBY.PK) Genentech unit and biotechnology firm Biogen Idec Inc. (BIIB: Quote) do not infringe two patents of French drug maker Sanofi SA (SNY: Quote,SNYNF.PK).

Genentech's Avastin, which had sales of 5.29 billion Swiss francs in 2011, is a blockbuster drug for treatment of cancers related to colon, lung, kidney and brain. Rituxan had sales of 6.01 billion Swiss francs in 2011. Rituxan is currently co-marketed by Biogen Idec and Genentech in the U.S.

In a ruling posted on the court's website, the U.S. Court of Appeals for the Federal Circuit said that Sanofi's '522 and '140 patents were not infringed by Genentech and Biogen. The court ruled that the district court had not erred in its judgment.

In October 2008, Sanofi filed a lawsuit for infringement of the two patents, alleging that Genentech and Biogen made use of an infringing enhancer in producing the antibody-based drugs Rituxan and Avastin.

SNY closed Thursday's trading at $38.45, down $0.23 or 0.59 percent on a volume of 1.86 million shares.

Click here to receive FREE breaking news email alerts for Sanofi and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
With trading resuming following the long, holiday weekend, stocks showed a lack of direction throughout the trading session on Tuesday before ending the day mixed. The markets largely held on to the bulk of their recent gains. The Islamic State (IS), a Sunni extremist group previously known as Islamic State of Iraq and the Levant (ISIL), has released a video purporting to show the beheading of US journalist Steven Sotloff, media reports said Tuesday. According to reports, the video also showed a masked man threatening to execute a British man named David Haines. He also warned governments to stay away "this evil allian Less than a month after resigning from Congress, former House Majority Leader Eric Cantor, R-Virg., has made the move from Washington to Wall Street by joining boutique investment bank Moelis & Co. A statement from Moelis said Cantor will serve as Vice Chairman and Managing Director and also be elected to the company's Board of Directors.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.